Edition:
India

AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

16.99USD
13 Dec 2018
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$16.99
Open
$17.59
Day's High
$17.65
Day's Low
$16.85
Volume
259,766
Avg. Vol
221,570
52-wk High
$26.08
52-wk Low
$11.95

Latest Key Developments (Source: Significant Developments)

AMAG Pharmaceuticals Pays Off $475 Million Of Senior Secured Notes
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - AMAG Pharmaceuticals Inc ::AMAG PHARMACEUTICALS PAYS OFF $475 MILLION OF SENIOR SECURED NOTES.AMAG PHARMACEUTICALS INC - REDEEMED $475 MILLION OF ITS OUTSTANDING 7.875% SENIOR NOTES, USING PROCEEDS FROM SALE OF CORD BLOOD REGISTRY.  Full Article

Palatin Technologies Receives FDA Acceptance For Review Of Bremelanotide NDA
Monday, 4 Jun 2018 

June 4 (Reuters) - Palatin Technologies Inc ::PALATIN TECHNOLOGIES ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF BREMELANOTIDE NDA.PALATIN TECHNOLOGIES ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF BREMELANOTIDE NDA.PALATIN TECHNOLOGIES INC - PDUFA GOAL DATE FOR COMPLETION OF FDA REVIEW OF BREMELANOTIDE NDA IS MARCH 23, 2019.PALATIN TECHNOLOGIES - FDA'S ACCEPTANCE OF NDA TRIGGERS $20 MILLION MILESTONE PAYMENT TO CO UNDER ITS LICENSE AGREEMENT WITH AMAG PHARMACEUTICALS.  Full Article

AMAG Pharmaceuticals and Sandoz Enters Stipulation Of Dismissal
Friday, 23 Mar 2018 

March 23 (Reuters) - Amag Pharmaceuticals Inc ::AMAG PHARMACEUTICALS - ‍CO, SANDOZ ENTERED STIPULATION OF DISMISSAL, PURSUANT TO SETTLEMENT AGREEMENT, THAT DISMISSES, RESOLVES PATENT LITIGATION​.AMAG PHARMACEUTICALS - ‍SETTLEMENT DISMISSES & RESOLVES PATENT LITIGATION RELATED TO CO'S FERAHEME, 30 MG/ML, 17 ML SINGLE DOSE VIALS FOR INTRAVENOUS USE​.AMAG PHARMACEUTICALS - ‍IF SANDOZ RECEIVES FDA APPROVAL BY A CERTAIN DATE, SANDOZ MAY LAUNCH GENERIC VERSION OF FERAHEME ON JULY 15, 2021, OR EARLIER​.AMAG PHARMACEUTICALS - ‍SANDOZ TO PAY SALES ROYALTY OF GENERIC VERSION OF FERAHEME TO AMAG UNTIL EXPIRATION OF LAST FERAHEME PATENT LISTED IN ORANGE BOOK​.  Full Article

AMAG Reports Q4 Earnings Of $0.10 Per Share
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Amag Pharmaceuticals Inc ::AMAG REPORTS 2017 FINANCIAL RESULTS AND COMPANY UPDATE.Q4 EARNINGS PER SHARE $0.10.TOTAL GAAP REVENUES FOR Q4 OF 2017 WERE $158.3 MILLION, COMPARED WITH $151.6 MILLION.NON-GAAP REVENUE TOTALED $159.7 MILLION IN Q4 OF 2017, UP FROM $153.0 MILLION.SAYS AFFIRMS FINANCIAL GUIDANCE FOR 2018.QUARTERLY TOTAL REVENUES $158.3 MILLION VERSUS $151.6 MILLION.  Full Article

AMAG Gets FDA Approval Of Makena Subcutaneous Auto-Injector
Thursday, 15 Feb 2018 

Feb 14 (Reuters) - Amag Pharmaceuticals Inc ::AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF MAKENA® (HYDROXYPROGESTERONE CAPROATE INJECTION) SUBCUTANEOUS AUTO-INJECTOR TO REDUCE THE RISK OF PRETERM BIRTH IN CERTAIN AT-RISK WOMEN.AMAG PHARMACEUTICALS - EXPECTS TO FILE A NEW DRUG APPLICATION THIS QUARTER FOR A NEW CHEMICAL ENTITY (BREMELANOTIDE) ​.AMAG PHARMACEUTICALS INC - ‍EXPECTS SUBCUTANEOUS AUTO-INJECTOR TO BE AVAILABLE IN SECOND HALF OF MARCH​.AMAG PHARMACEUTICALS INC - WILL CONTINUE TO OFFER IM FORMULATION OF MAKENA IN BOTH SINGLE-DOSE AND MULTI-DOSE VIALS​.AMAG PHARMACEUTICALS INC - ‍MAKEN'S 7-YEAR ORPHAN DRUG EXCLUSIVITY EXPIRED EARLIER THIS MONTH​.AMAG PHARMACEUTICALS - ANNOUNCES FDA APPROVAL OF MAKENA (HYDROXYPROGESTERONE CAPROATE INJECTION) SUBCUTANEOUS AUTO-INJECTOR ‍​.  Full Article

AMAG Pharmaceuticals Sees Q4 2017 Revenue $156 Mln to $163 Mln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - AMAG Pharmaceuticals Inc ::AMAG PHARMACEUTICALS ANNOUNCES PRELIMINARY 2017 FINANCIAL RESULTS AND PROVIDES 2018 GUIDANCE.SEES Q4 2017 REVENUE $156 MILLION TO $163 MILLION.SEES FY 2017 REVENUE $613 MILLION TO $620 MILLION.SEES FY 2017 REVENUE UP 15 PERCENT.SEES Q4 2017 REVENUE UP ABOUT 5 PERCENT.- ‍FOR Q4 OF 2017, AMAG EXPECTS AN OPERATING LOSS OF BETWEEN $6 MILLION AND $16 MILLION​.- ‍EXPECTS 2017 TOTAL GAAP REVENUE TO BE BETWEEN $607 MILLION AND $614 MILLION​.SEES ‍ 2017 OPERATING LOSS OF BETWEEN $292 MILLION AND $302 MILLION (DUE PRIMARILY TO A Q3 NON-CASH ACCOUNTING CHARGE)​.SEES ‍2018 TOTAL GAAP REVENUE $500 MILLION - $560 MILLION​.SEES ‍2018 GAAP OPERATING LOSS $147 MILLION - $117 MILLION​.Q4 REVENUE VIEW $161.1 MILLION -- THOMSON REUTERS I/B/E/S.FY2017 REVENUE VIEW $616.0 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $504.1 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Palatin Technologies signs licensing agreement with Kwangdong Pharma
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Palatin Technologies :Palatin Technologies announces signing of licensing agreement with Kwangdong Pharmaceutical for Republic of Korea.A NDA anticipated to be filed with U.S. Food and Drug Administration in Q1 of calendar year 2018​.  Full Article

Amag Pharmaceuticals Q3 loss per share $4.31
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Amag Pharmaceuticals Inc :Amag Pharmaceuticals announces third quarter 2017 financial results and business highlights.Q3 loss per share $4.31.Q3 earnings per share view $0.18 -- Thomson Reuters I/B/E/S.Q3 revenue $153.7 million versus I/B/E/S view $168.5 million.Amag Pharmaceuticals Inc - ‍co has updated 2017 Makena revenue guidance to between $385 million and $395 million​.  Full Article

Amag Pharmaceuticals announces U.S. FDA filing acceptance
Thursday, 31 Aug 2017 

Aug 31 (Reuters) - Amag Pharmaceuticals Inc ::Amag announces U.S. FDA filing acceptance and six-month review of Feraheme® (Ferumoxytol) for the treatment of all adult patients with iron deficiency anemia.Amag Pharmaceuticals Inc - ‍prescription drug user fee act target action date of February 2, 2018 for feraheme​.  Full Article

Amag Pharmaceuticals Q2 loss per share $0.40
Thursday, 3 Aug 2017 

Aug 3 (Reuters) - Amag Pharmaceuticals Inc ::Amag pharmaceuticals announces second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.40.Q2 earnings per share view $1.34 -- Thomson Reuters I/B/E/S.Q2 revenue $158.4 million versus I/B/E/S view $158.6 million.Amag pharmaceuticals inc - ‍reaffirming 2017 financial guidance​.Amag pharmaceuticals inc - sees ‍ 2017 GAAP total revenue $625 million - $685​ million.  Full Article